Sagimet Biosciences Inc. (NASDAQ:SGMT – Get Free Report) Director George Kemble sold 18,844 shares of Sagimet Biosciences stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $7.46, for a total value of $140,576.24. Following the sale, the director directly owned 62,161 shares in the company, valued at $463,721.06. This trade represents a 23.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Sagimet Biosciences Price Performance
SGMT stock opened at $7.27 on Wednesday. Sagimet Biosciences Inc. has a 1-year low of $4.50 and a 1-year high of $10.27. The company has a market capitalization of $236.86 million, a price-to-earnings ratio of -5.43 and a beta of 3.35. The business has a 50 day simple moving average of $7.12 and a two-hundred day simple moving average of $6.36.
Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.06. Sell-side analysts anticipate that Sagimet Biosciences Inc. will post -1.15 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several research firms recently weighed in on SGMT. Oppenheimer reaffirmed an “outperform” rating on shares of Sagimet Biosciences in a research note on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Sagimet Biosciences in a report on Friday, July 17th. Canaccord Genuity Group raised their price objective on Sagimet Biosciences from $28.00 to $49.00 and gave the company a “buy” rating in a research report on Monday, May 4th. Citizens Jmp cut their price objective on Sagimet Biosciences from $35.00 to $12.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 19th. Finally, Guggenheim reduced their target price on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $25.57.
Get Our Latest Research Report on SGMT
About Sagimet Biosciences
Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.
In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.
Featured Stories
- Five stocks we like better than Sagimet Biosciences
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
